Press release content from Business Wire. The AP news staff was not involved in its creation.
Worldwide Skincare Products Industry to 2026 - Escalating Demand For Anti-Aging and Anti-Pollution Ranges - ResearchAndMarkets.com
April 16, 2021 GMT
DUBLIN (BUSINESS WIRE) Apr 16, 2021
The Global Skincare Products Market was valued at USD 140.92 billion in 2020 and is projected to grow at a CAGR of 4.69% during the forecast period 2021 - 2026.
ADVERTISEMENT
The COVID-19 pandemic influenced consumers’ spending habits and purchase decisions leading to a slight decline in the market growth by 1.12% in 2020 owing to various governments imposing multiple measures intended to slowdown spread of the COVID-19. Some basic initiatives include social isolation directives, limitations on business opening hours, and travel restrictions. But, the sales of the product through on-line outlet escalated during the pandemic period. For Instance, Zalando, Europe’s fashion and lifestyle e-commerce co
Press release content from Business Wire. The AP news staff was not involved in its creation.
Insights on the Smart Inhalers Global Market to 2025 - Competitive Analysis and the Impact of COVID-19 - ResearchAndMarkets.com
April 16, 2021 GMT
DUBLIN (BUSINESS WIRE) Apr 16, 2021 The Global Smart Inhalers Market is estimated to be USD 118.35 Mn in 2020 and is expected to reach USD 257.38 Mn by 2025, growing at a CAGR of 16.81%. Key factors such as growth in respiratory disorders such as asthma and Chronic Obstructive Pulmonary Diseases (COPD) and growing acceptance towards digital healthcare equipment have driven the demand for the smart inhaler market. Similarly, the demand for real-time monitoring devices in the healthcare sector has additionally supported the growth of the market further.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology
EhaveApril 16, 2021 GMT
MIAMI, April 16, 2021 (GLOBE NEWSWIRE) Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to launch brain mapping ketamine clinical trials using Brain Scientific technology later this year. The clinical trial will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders.
The trial, which is designed to enroll 35 patients, is expected to start in the second half of 2021. Ehave is currently completing the necessary preclinical studies necessary to begin enrolling patients in the trial. The average drop out ratio of clinical trials is around 15 % and Ehave will need at least 25-30 patients’ egg data to es